What are the Therapeutic Strategies Targeting Ras?
Targeting Ras directly has been a challenge due to its high affinity for GTP/GDP and the lack of suitable binding pockets for small molecules. However, recent advances have led to the development of KRAS G12C inhibitors like sotorasib and adagrasib, which have shown promise in clinical trials. Other strategies include targeting downstream effectors of Ras signaling, such as MEK and ERK inhibitors, and exploiting synthetic lethality by targeting pathways that Ras-mutant cells rely on for survival.
